Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Sco ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.There’s value to be had in buying boring businesses that deliver shareholder returns year in and out. Such companies may not be household names like NVIDIA C ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 ... [+] million, “primarily for debt paydown and general corporate purposes,” the drugstore giant said Thursday night, Feb. 6, 2025. In this photo, Walgreens signage is displayed outside a Walgreens store June 4, 2003 in Niles, Illinois. (Photo by Tim Boyle/Getty Images)Getty ImagesWalgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for deb ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FOR THE QUARTERLY PERIOD ENDED December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 CENCORA, INC. (Exact name of registrant as specified in its charter) | Delaware | | | 23-30 ...

Cencora, Inc. (COR) reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of $3.73, which beat the Zacks Consensus Estimate of $3.50 by 6.6%. The bottom line also improved 13.7% year over year.GAAP EPS was $2.50, down 16.1% from the year-ago period’s level.The decline in GAAP EPS has likely resulted from the absence of a credit of $78.9 million related to litigation and opioid-related expenses recorded in the year-ago quarter.Stay up-to-date with all quarterly releases: See Zacks Earnings Cal ...

Financial Data and Key Metrics Changes - Cencora reported a revenue growth of 13% in Q1 2025, reaching $81.5 billion, primarily driven by strong performance in the U.S. healthcare solutions segment [22][8] - Adjusted diluted EPS increased by 14% to $3.73, prompting the company to raise its full-year adjusted diluted EPS guidance to a range of $15.25 to $15.55 [21][32] - Consolidated gross profit was $2.5 billion, up 6%, with a gross profit margin of 3.11%, a decrease of 20 basis points due to increased sales of low-margin GLP-1 products [23][24] Business Line Data and Key Metrics Changes - U.S. healthcare solutions segment revenue was $74 billion, up 14%, with GLP-1 product sales increasing by 53% year-over-year [26][27] - International healthcare solutions segment revenue was $7.5 billion, up approximately 6% on an as-reported basis and nearly 9% on a constant currency basis [28] Market Data and Key Metrics Changes - The company experienced strong prescription utilization trends in the U.S. healthcare solutions segment, contributing to overall revenue growth [21][26] - The international healthcare solutions segment's operating income was $182 million, down 3% on an as-reported basis, but up 3% on a constant currency basis [28] Company Strategy and Development Direction - Cencora is focused on advancing its leadership in specialty healthcare, enhancing efficiency through technology, and maintaining a customer-centric approach [10][15] - The acquisition of Retina Consultants of America (RCA) is part of the strategy to expand leadership in specialty healthcare and support community providers [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capitalize on positive industry trends and innovation, with a focus on driving value for stakeholders [19][39] - The company anticipates a challenging second quarter due to COVID-19 vaccine headwinds and expects to see improved performance in the international segment later in fiscal 2025 [38][62] Other Important Information - The company used $2.7 billion in cash during the quarter, resulting in negative adjusted free cash flow of $2.8 billion, but expects full-year adjusted free cash flow to be in the range of $2 billion to $3 billion [25][30] - Cencora's capital allocation strategy prioritizes deleveraging following the RCA acquisition [25] Q&A Session Summary Question: Strategic positioning in specialty business - Management emphasized a pharmaceutical-centered strategy and the importance of a strong customer portfolio to drive growth in specialty healthcare [44][46] Question: Revenue guidance and potential deceleration - Management noted that the revenue growth guidance reflects assumptions about GLP-1 growth and the impact of Humira's conversion to biosimilars [52][54] Question: World Courier business performance - Management acknowledged a challenging quarter for the World Courier business due to subdued clinical trial activity but expects improvement later in fiscal 2025 [61][62] Question: Update on Walgreens contract discussions - Management confirmed ongoing engagement with Walgreens to create value and that guidance includes assumptions regarding the contract [71][73] Question: MSO business challenges and physician enablement - Management highlighted the importance of physician leadership and value creation in the MSO model [77][79] Question: Competitive environment in ophthalmology MSO space - Management expressed confidence in RCA's leadership position and the ability to attract physicians and practices [83][84] Question: Guidance revision for U.S. business on an organic basis - Management indicated that the U.S. segment's performance is above initial guidance, driven by strong utilization trends [88] Question: COVID headwind impact - Management confirmed that the COVID-related headwind was as expected, with no significant contribution from exclusive COVID therapies in the current year [120]

For the quarter ended December 2024, Cencora (COR) reported revenue of $81.49 billion, up 12.8% over the same period last year. EPS came in at $3.73, compared to $3.28 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $78.12 billion, representing a surprise of +4.31%. The company delivered an EPS surprise of +6.57%, with the consensus EPS estimate being $3.50.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ex ...

Core Insights - Cencora reported quarterly earnings of $3.73 per share, exceeding the Zacks Consensus Estimate of $3.50 per share, and showing an increase from $3.28 per share a year ago, resulting in an earnings surprise of 6.57% [1] - The company achieved revenues of $81.49 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.31% and up from $72.25 billion year-over-year [2] - Cencora's stock has increased approximately 12% since the beginning of the year, outperforming the S&P 500's gain of 2.7% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.25 on revenues of $75 billion, while for the current fiscal year, the estimate is $15.14 on revenues of $320.36 billion [7] - The estimate revisions trend for Cencora is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Cencora belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, which may impact stock performance [8] - Medpace, another company in the same industry, is expected to report quarterly earnings of $2.97 per share, reflecting a year-over-year increase of 20.7%, with revenues projected at $536.37 million, up 7.6% from the previous year [9][10]

February 5, 2025 Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "poten ...

Revenue Performance - Revenue for the first quarter of fiscal 2025 was $81.5 billion, representing a 12.8 percent increase year-over-year, driven by a 13.6 percent increase in the U.S. Healthcare Solutions segment[1][5] - U.S. Healthcare Solutions revenue was $74.0 billion, an increase of 13.6 percent year-over-year, with segment operating income rising 9.9 percent to $767.3 million[8][10] - International Healthcare Solutions revenue was $7.5 billion, a 5.5 percent increase year-over-year, with operating income decreasing by 2.9 percent[10] - Total revenue for the same period increased by 12.8% year-over-year, reaching $81.49 billion, driven by a 13.6% increase in U.S. Healthcare Solutions revenue[32] - For Q1 fiscal 2025, the company's revenue was $81.5 billion, negatively impacted by foreign currency translation of $216.8 million, resulting in constant currency revenue of $81.7 billion[42] - The International Healthcare Solutions segment reported revenue of $7.5 billion, with a constant currency revenue of $7.7 billion after accounting for foreign currency translation[42] Earnings and Income - Adjusted diluted EPS guidance for fiscal 2025 has been raised to a range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45[2][16] - Operating income for the first quarter was $706 million, a 14.2 percent decrease compared to the same period last year, primarily due to increased operating expenses[4][5] - Adjusted operating income for the first quarter was $949 million, a 7.2 percent increase compared to the prior year[9] - Net income attributable to Cencora, Inc. was $488,600, a decrease of 18.8% from $601,500 in the prior year, resulting in diluted earnings per share of $2.50, down 16.1%[25] - Adjusted Non-GAAP net income was $727,796, reflecting a 13.7% increase compared to the prior year, with adjusted diluted earnings per share of $3.73[27] - GAAP net income for the three months ended December 31, 2023, was $601.5 million, with diluted earnings per share of $2.98[30] Expenses and Costs - Total operating expenses increased by 12.5% to $1,851,784, with distribution, selling, and administrative expenses rising by 5.2% to $1,472,055[25] - The company incurred a $35.5 million loss on the divestiture of non-core businesses during the quarter[27] - Interest expense decreased by 31.1% to $27,933, down from $40,564 in the previous year[25] - Net interest expense decreased by 31.1 percent to $27.9 million, attributed to higher interest income from increased cash balances[5][9] Dividends and Shareholder Returns - The company declared a quarterly cash dividend of $0.55 per common share, payable on March 3, 2025[17] Acquisitions and Strategic Moves - The acquisition of Retina Consultants of America was completed on January 2, 2025, enhancing the company's leadership in Specialty healthcare services[3][11] - The company plans to finance a portion of the upcoming acquisition of Retina Consultants of America with $1.8 billion in senior notes[37] Tax and Financial Metrics - The effective tax rate for the first quarter was 20.4 percent, down from 23.0 percent in the prior year[5] - The adjusted effective tax rate is calculated by dividing adjusted income tax expense by adjusted income before income taxes, providing a clearer view of the company's tax performance excluding unusual items[44] Cash Flow and Liquidity - Cash and cash equivalents at the end of the period totaled $3.22 billion, an increase from $3.13 billion at the end of the previous quarter[35] - The company experienced a net cash used in operating activities of $2.72 billion, compared to $885.16 million provided in the same period last year[37] - Long-term debt increased to $5.94 billion, up from $3.81 billion in the previous quarter[35] Non-GAAP Measures and Adjustments - Adjusted diluted earnings per share excludes impacts from antitrust litigation settlements, LIFO expense, and other non-recurring items, reflecting ongoing operational performance[44] - Adjusted net income attributable to the company excludes unusual, non-operating, unpredictable, non-recurring, or non-cash items, providing a clearer picture of ongoing performance[44] - Adjusted gross profit margin is calculated as adjusted gross profit divided by total revenue, providing insight into the company's core operating performance[41] - The company emphasizes the importance of non-GAAP financial measures to evaluate operating performance and financial planning[41]